Biotechnology

Intensity Therapeutics

Intensity Therapeutics Inc. to Present New Clinical Research at 2025 San Antonio Breast Cancer Symposium

Intensity Therapeutics released FY2025 Q3 earnings on November 6 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.062 (forecast USD -0.0633)

Intensity Therapeutics released FY2025 9 Months Earnings on November 6 (EST), with actual revenue of USD 0 and EPS of USD -0.417

Wasserman Analyst Rates Intensity Therapeutics, Inc. as Mild Buy

Intensity Therapeutics released FY2025 Q2 earnings on August 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1344 (forecast USD -0.17)

Intensity Therapeutics released FY2025 Semi-Annual Earnings on August 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.3454

Intensity Therapeutics Focuses on Developing Innovative Immunotherapy for Cancer

Intensity Therapeutics' INT230-6 Achieves 100% Response Rate in MPNST

Intensity Therapeutics Announces Early Results of INVINCIBLE-4 Study

Intensity Therapeutics to Present Phase 3 Clinical Trial for Metastatic Soft Tissue Sarcoma at ASCO Annual Meeting

Intensity Therapeutics Partners With Christine Handy To Raise Awareness For Early Breast Cancer Treatment Options

Intensity Therapeutics released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2205 (forecast USD -0.195)

Intensity Therapeutics Inc reports Q1 EPS of -0.22 dollars

Intensity Therapeutics Advances INVINCIBLE-4 Study Despite Funding Constraints

Biotech Company INTS Showcases New Cancer Treatment Drug Amid Financial Challenges and Declining Stock Prices

Intensity Therapeutics released FY2024 annual earnings on March 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.1697 USD (forecast -1.1675 USD)

Intensity Therapeutics released FY2024 Q4 earnings on March 13 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2208 USD (forecast -0.2225 USD)

Intensity Therapeutics released FY2024 Q3 earnings on November 13 (EST), with actual revenue of 0 USD and EPS of -0.2544 USD (forecast EPS was -0.305 USD)

Intensity Therapeutics released FY2024 Cumulative 3Q Earnings on November 13 (EST), Revenue: 0, EPS: -0.9527

Intensity Therapeutics released FY2023 Q4 earnings on March 14 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2304 USD (forecast -0.18 USD)

Aimei Health Tech

Oriental Culture

Netcapital

Lion

JX Luxventure

ALPHAVEST ACQUISITION CORP ORD USD0.0001(S/R 22/01/26)

Designer Brands

Horizon Space Acquisition I

Cypherpunk Tech

Alexander & Baldwin

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap